| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-03-08 | Kite Pharma (USA - CA) | $409.7 million | private placement | Private placement | ||
| 2017-02-27 | Exonics Therapeutics (USA - TX) | $ 5 million | financing round | CureDuchenne Ventures (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases | Financing round |
| 2017-02-22 | Oncternal Therapeutics (USA - CA) | $18.4 million | series B financing round | Cancer - Oncology - Rare diseases | Series B financing round | |
| 2017-02-21 | Auris Medical (Switzerland) | $9.1 million | private placement | Otorhinolaryngology | Private placement | |
| 2017-02-20 | Centauri Therapeutics (UK) | £4.2 million (€ million) | financing round | Animatrix Capital (UK) private investors | Infectious diseases | Financing round |
| 2017-02-15 | Signum Biosciences (USA - NJ) | $ 3 million | grant | National Institute of Allergy and Infectious Diseases (NIAID) (USA) | Dermatological diseases | Grant |
| 2017-02-14 | Inventiva (France) | € 48 million | IPO | Fibrotic diseases - Hepatic diseases - Liver diseases | IPO | |
| 2017-02-13 | Emergent Biosolutions (USA - MD) | up to $30.5 million | grant | Biomedical Advanced Research and Development Authority (BARDA) (USA) | Grant | |
| 2017-02-10 | Santhera Pharmaceuticals (Switzerland) | CHF 60 million (€ 56.18 million) | Rare diseases - Genetic diseases - Hematological diseases | Private placement | ||
| 2017-02-09 | Polyphor (Switzerland) | CHF 2.3 million (€ 2.15 million) | grant | Wellcome Trust (UK) | Infectious diseases | Grant |
| 2017-02-08 | Coherus Biosciences (USA - CA) | private placement | Private placement | |||
| 2017-02-08 | Acticor Biotech (France) | €2,9 million | financing round | Cap Decisif Management (France) | Cardiovascular diseases - Cerebrovascular diseases | Financing round |
| 2017-02-08 | Galena Biopharma (USA - OR) | private placement | Private placement | |||
| 2017-02-07 | Prexton Therapeutics (Switzerland) | € 29 million | series B financing round | Forbion Capital Partners (The Netherlands) Seroba Life Sciences (Ireland) Merck Ventures (The Netherlands) Ysios Capital (Spain) Sunstone Capital (Denmark) | Neurodegenerative diseases - CNS diseases | Series B financing round |
| 2017-02-07 | Lysogene (France) | € 22.6 million | IPO | Sofinnova Partners (France) BpiFrance (France) Novo A/S (Denmark) Financière Arbevel (France) Alto Invest (France) | Rare diseases - Genetic diseases | IPO |
| 2017-02-07 | OncoSNIPE® consortium (Oncodesign, Expert System, Sword, Acobiom, Hôpitaux Universitaires de Strasbourg, Centre George François Leclerc, Institut Paoli Calmettes) | €7.7 million | subvention | Bpifrance (France) | Cancer - Oncology | Subvention |
| 2017-01-20 | Affimed (Germany) | private placement | Cancer - Oncology | Private placement | ||
| 2017-01-20 | Stemline Therapeutics (USA - NY) | $45 million | private placement | Cancer - Oncology | Private placement | |
| 2017-01-19 | Anavex Life Sciences (USA - NY) | $ 0.6 million | grant | Rettsyndrome.org (USA - OH) | Neurological diseases - CNS diseases | Grant |
| 2017-01-19 | Octimet Oncology (Belgium) | € 11.3 million | series A financing round | V-Bio Ventures (Belgium) Fund+ (Belgium) DROIA Oncology Ventures (Luxembourg/Belgium) OMNES Capital (France) | Cancer - Oncology | Series A financing round |
